A

Rating buyAI MemoPost-earnings T+1

Agilent

As of 2026-08-27/Post-earnings T+1/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

—

Key catalyst

Q3 FY2026 beat and raised full-year outlook • 2026-08-26

Base target: $164 / p=50% prob

Biggest risk

The beat was partly helped by tariff refunds, while the stock’s initial reaction already moved it near $160 and near its recent high. The packet does not provide a complete post-print analyst revision set, so confirmation of durable estimate upgrades remains limited.

Invalidation

Break below $145 or thesis failure.

What would change my mind?

The Q3 print was materially constructive: revenue exceeded the stored $1.84 billion consensus, non-GAAP EPS exceeded the $1.49 consensus, and FY2026 EPS guidance rose to $6.18-$6.21. Segment growth was broad and management described improving end markets and stronger demand [#SEC-8K-2026-08-26].

Research note

Recommendation

buy

Confidence

high

As of

2026-08-27

Base target

$164

p=50%

Bull target

$177

p=30%

Bear target

$145

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Positive post-print reaction, with limited immediate upside
Temporary tariff-refund benefit creates earnings-quality risk
Cross-segment demand supports delivery of raised FY2026 targets

BearKey bullets

Analyst target breadth, estimate revisions, and refreshed peer read-through are incomplete in the evidence packet.
Execution must meet Q4 revenue guidance of $1.98-$2.00 billion and non-GAAP EPS guidance of $1.71-$1.74.
Q3 EPS and margin benefited from tariff refunds; Q4 guidance excludes future refunds [#SEC-8K-2026-08-26].

WatchKey bullets

Q3 FY2026 beat and raised full-year outlook

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $164 (p=50%)

Target spread vs base: +8% / -12%

Scenario probabilities

Bull Target: $177 (p=30%)Base Target: $164 (p=50%)Bear Target: $145 (p=20%)

Commentary

The company’s SEC-filed earnings release provides strong primary evidence for a positive thesis: Q3 beat expectations and FY2026 guidance increased [#SEC-8K-2026-08-26]. Secondary coverage reported an approximately 3.17% after-hours gain. Social sentiment, options data, and broad analyst-revision data are unavailable, so this remains constructive but not maximum-conviction.

As of 2026-08-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Positive post-print reaction, with limited immediate upside
Temporary tariff-refund benefit creates earnings-quality risk
Cross-segment demand supports delivery of raised FY2026 targets

Scenarios

Bull Target (Scenario probability)

$177 / p=30% prob

Base Target (Scenario probability)

$164 / p=50% prob

Bear Target (Scenario probability)

$145 / p=20% prob

Analysis 2026-08-27 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.78

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-26
Q3 FY2026 beat and raised full-year outlook
Agilent reported $1.88 billion revenue, 7.3% core growth, and non-GAAP EPS of $1.62, while raising FY2026 revenue, margin-expansion, and EPS guidance. Management cited improving end markets, stronger regional demand, and customer response to new products [#8-K-2026-08-26][#SEC-8K-2026-08-26].
Prob 85.00% • Move 4.50% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Positive post-print reaction, with limited immediate upside
2026-08-27
Secondary market coverage reported approximately a 3.17% after-hours gain toward $160 after the beat and guidance raise. The initial reaction supports constructive sentiment, but the move leaves less room for an additional near-term rerating.
Prob 75% • Move 3% • Priced-in 80%
Temporary tariff-refund benefit creates earnings-quality risk
2026-10-31
Q3 non-GAAP EPS included a $0.06 tariff-refund benefit and operating margin included an approximately 110-basis-point net benefit. Fourth-quarter guidance excludes future tariff-refund benefits, making the underlying run rate important for follow-through [#SEC-8K-2026-08-26].
Prob 60% • Move -2% • Priced-in 45%

Long-term Catalysts

Months to a year

Cross-segment demand supports delivery of raised FY2026 targets
2026-10-31
Q3 core growth was 10% in Life Sciences and Diagnostics, 5% in CrossLab, and 7% in Applied Markets. Sustaining this breadth, alongside management’s stated improving end markets and product momentum, could support the raised FY2026 outlook [#8-K-2026-08-26].
Prob 65% • Move 7% • Priced-in 55%

Risks

Analyst target breadth, estimate revisions, and refreshed peer read-through are incomplete in the evidence packet.
Execution must meet Q4 revenue guidance of $1.98-$2.00 billion and non-GAAP EPS guidance of $1.71-$1.74.
Q3 EPS and margin benefited from tariff refunds; Q4 guidance excludes future refunds [#SEC-8K-2026-08-26].
The post-earnings move reduces near-term valuation headroom and raises the risk of profit-taking if momentum slows.

Peers

Symbol	Summary
WAT	Direct analytical-instrument comparator for chromatography, replacement-cycle, and service-attachment trends; identified as a principal competitor in Agilent’s 10-K [#10-K-2025-12-22].
TMO	Large life-science tools benchmark useful for end-market demand and mix comparisons, though broader than Agilent [#10-K-2025-12-22].
DHR	Relevant diagnostics and instruments comparator for workflow and execution read-through; peer comparison is not refreshed in the current packet [#10-K-2025-12-22].
BRKR	Focused analytical-instruments peer for testing whether replacement-cycle and high-end workflow demand are broad-based; current peer operating data is unavailable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-27

Loading AI feed…

Symbol

Summary

WAT

Direct analytical-instrument comparator for chromatography, replacement-cycle, and service-attachment trends; identified as a principal competitor in Agilent’s 10-K [#10-K-2025-12-22].

TMO

Large life-science tools benchmark useful for end-market demand and mix comparisons, though broader than Agilent [#10-K-2025-12-22].

DHR

Relevant diagnostics and instruments comparator for workflow and execution read-through; peer comparison is not refreshed in the current packet [#10-K-2025-12-22].

BRKR

Focused analytical-instruments peer for testing whether replacement-cycle and high-end workflow demand are broad-based; current peer operating data is unavailable.